top of page

Publications

2026

  • Fan K, Rasti, M, Khan R, Ziyaeyan A, Barazandeh AF, Low R, Garcia J, Safara S, Nouri S, Robb KP, Gandhi R, Viswanathan S. TGFB1-Engineered induced mesenchymal stromal cells exhibit high immunomodulatory potency and durably reprogram synovial macrophages in osteoarthritis. bioRxiv​

  • Banh L, Perera K, Lobo BR, Walz K, Cheung KK, Chatterjee R, Bonnell E, Li K, Moon BU, Gandhi R, Young E, Viswanathan S. Human knee osteoarthritis patient-specific cartilage-on-a-chip model captures donor differences to stressors and treatments. bioRxiv/Nature Communications. ​​

  • Kolade O, Robb KP, Audet J, Viswanathan S. Combined computational and experimental framework links donor heterogeneity to mesenchymal stromal cells potency and critical processing parameters. bioRxiv/Stem Cell Translational Medicine. ​

  • Ziyaeyan A, Rasti M, Gandhi R, Oikonomopoulou K, Chandran V, Viswanathan S. Joint tissue explant model using psoriatic arthritis synovial fluid as a tool to capture patient-specific responses to treatments. bioRxiv/Rheumatology.

  • Creane M, Grilley BJ, Forte M, Sanchez-Guijo F, Jorgenson C, Martin I, Ikonomou L, Viswanathan S. Cell therapies: are we doing enough to protect patients and address the barriers to patient access?  Cytotherapy. JIF: 4.15​​

  • Rasti M, Barazandeh AF, Nouri S, Robb KP, Low R, Kolade O, Fan K, Gandhi R, Viswanathan S. Mesenchymal stromal cells immunosuppress osteoarthritis synovial fluid modulated monocytes via IL-6 and CCL2. Cell Death and Disease.​

  • Robb KP, Rabani R, Vohra S, Singh S, Kolade O, Chahal J, Audet J, Perruccio AV, Naraghi A, Gandhi R, Espin-Garcia O, Viswanathan S. Responders vs. non-responders to mesenchymal stromal cells in knee osteoarthritis: mechanistic correlates of donor cell and patient features. Stem Cell Reports. JIF: 4.70​

  • Barry J, Abranches E, Baptista R, Barry C, Brandsten C, Bruce K, Carpenter M, Cavagnaro J, Collins L, Csaszar E, Dashnau J, Devilla D, Fynes K, Gabaldo M, Hao J, Harel-Adar T, Hei D, Henchcliffe C, Hidalgo-Simon A, Hollands J, Hursh D, Jackman S, Kelly K, Kim JH, Kim H, Kino-oka M, Lakshmipathy U, Lamb T, Lazic SE, Loring JF, Ludwig, TE, Mariappan I, Monville C, Mountford J, Nagy A, Okano H, Pellegrini G, Persson A, Prutton K, Rasko JR, Sareen D, Sato Y,  Shnaiderman A, Stacey G, Svendsen C, Tomishima M, Trounson A, Viswanathan S, Wang S, Wydenbach K, Zhang A, Zylberberg C, Mosher JT, Bharti K. Charting the translational pathway: ISSCR best practices for the development of PSC-Derived Therapies. Stem Cell Reports. JIF: 4.70

2025

  • Shokoohmand A, Patel NM, Braid L, Dominici M, Heng TSP, Ankrum JA, Barua J, Caicedo A, Creane M, Davies L, Santos CC, Enes SR, English K, Farge D, Fernández-García M, Galipeau J, Kadri N, Khoury M, Kilfeather S, Krampera M, Krasnodembskaya A, Lalu M, Blanc KL, Moll G, Nolta J, O’Kane C, Rocco PRM, Shi Y, Weiss DJ, Viswanathan S. Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions. Cytotherapy.  JIF:4.15​

  • Viswanathan S, Galipeau J. Hallmarks of MSCs: determining critical quality attributes for pharmacology and clinical use. Cell Stem Cell. JIF: 19.8​

  • LeBlanc K, Dazzi F,  English K, Farge D, Galipeau J,  Horowitz EM, Kadri N, Krampera M, Lalu MM, Nolta J, Patel NM, Shi Y, Weiss DJ, Viswanathan S. ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells. Cytotherapy. JIF:4.15​​​​

2024

  • Renesme L, Cobey K, Lalu M, Bubela T, Chinnadurai R, De Vos J, Dunbar R, Fergusson D, Freund D, Galipeau J, Horwitz E, Lê M, Matthay M, Moher D, Nolta J, Parker G, Phinney DG, Rao M, Rasko J, Rocco P, Rossi F, Rosu-Myles M, Viswanathan S, Thébaud B. Delphi-driven consensus definition for MSCs and clinical reporting guidelines for MSC-based therapeutics. Cytotherapy. JIF: 4.15 

  • Moon BU, Li K, Malic L, Morton K, Shao H, Banh L, Viswanathan S, Young EWK, Veres T. Reversible bonding in thermoplastic elastomer microfluidic platforms for harvestable 3D microvessel networks. Lab On a Chip. JIF: 6.22​

  • Ma Y, Nouri S, Pham DA, Ziyaeyan A, Chen Z, Morozova S, Chekini M, Banquy X, Adibnia V, Viswanathan S, Kumacheva E. Phytoglycogen nanolubricants with extended retention time in joints. Advanced Functional Materials. JIF: 19

  • Ferrari M, Taboni S, Chan H, Townson J, Gualtieri T, Franz L, Ruaro A, Mathews S, Daly M, Douglas C, Eu D, Sahovaler A, Muhanna N, Ventura M, Dey K, Pandini S, Pasini C, Re F, Bernardi S, Bosio K, Mattavelli D, Doglietto F, Joshi S, Gilbert R, Nicolai P, Viswanathan S, Sartore L, Russo D, Irish J. Hydrogel-chitosan and polylactic acid-polycaprolactone bioengineered scaffolds for reconstruction of mandibular defects: a preclinical in vivo study with assessment of translationally relevant aspects. Frontiers in Bioengineering and Biotechnology. JIF: 5.8

  • Bodenstein DF, Siebiger  G, Zhao Y, Clasky AJ, Mukkala AN, Beroncal EL, Banh L, Aslostovar L, Brijbassi S, Hogan SE, McCully JD, Mehrabian M, Petersen TH, Robinson LA, Walker M, Zachos C, Viswanthan S, Gu FX, Rotstein OD, Cypel M, Radisic M, Andreazza AC. Bridging the gap between in vitro and in vivo models: A way forward to clinical translation of mitochondrial transplantation in acute disease states. Stem Cell Research & Therapy. JIF: 7.39  ​

2023

  • Robb KP, Viswanathan S. Failure to launch mesenchymal stromal cell therapies: what's the path forward? Proceedings of the ISCT annual meeting roundtable held in May 2023. Cytotherapy. JIF: 4.15

  • Chinnadurai R, Viswanathan S, Guido M. Next generation mesenchymal stromal cell therapy manufacturing, potency and mechanism of action analysis. Frontiers in Immunology. JIF: 7.0

  • Copp G, Robb KP, Viswanathan S. Culture-expanded mesenchymal stromal cells and knee osteoarthritis – does it work? A review of clinical evidence, mechanism of action and roadmap for next steps. Cellular and Molecular Immunology. JIF: 12.17

2022

  • Viswanathan S, Blanc KL, Ciccocioppo R, Dagher G, Filiano AJ, Galipeau J, Krampera M, Krieger L, Lalu MM, Nolta J, Phinney DG, Rodríguez-Pardo V, Shi Y, Tarte K, Weiss DJ, Martin I. An ISCT MSC Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone marrow-MSCs and umbilical cord tissue-derived MSCs for research purposes. Cytotherapy. JIF: 4.15

  • Robb KP, Audet J, Gandhi, R, Viswanathan S. Putative critical quality attribute matrix identifies mesenchymal stromal cells with potent immunomodulatory and angiogenic “fitness” ranges in response to culture process parameters. Frontiers in Immunology. JIF: 7.0

  • Weiss DJ, Filiano A, Galipeau J, Khoury M, Krampera M, Lalu M, Blanc KL, Nolta J, Phinney DG, Rocco PRM, Shi Y, Tarte K, Viswanathan S, Martin I. An ISCT MSC Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for COVID-19: Time for a global registry. Cytotherapy. JIF: 4.15

  • Banh L, Cheung KK, Chan MWY, Young EWK, Viswanathan S, (2022) Advances in Organ-on-a-Chip Systems for Modelling Joint Tissue and Osteoarthritic Diseases. Osteoarthritis and Cartilage. JIF: 7.0

  • Sartore L, Pasini C, Pandini S, Dey K, Ferrari M, Taboni S, Chan HHL, Townson J, Viswanathan S, Mathews S, Gilbert RW, Irish JC, Re F, Nicolai P, Russo D. Hybrid core-shell polymer scaffold for bone tissue regeneration. International Journal of Molecular Sciences. JIF: 4.90

2021

  • Chan MWY, Gómez-Aristizábal A, Mahomed N, Gandhi R, Viswanathan S. A tool for evaluating novel osteoarthritis therapies using multivariate analyses of human cartilage-synovium. Osteoarthritis and Cartilage. JIF: 7.0

  • Viswanathan S, Ciccocioppo R, Galipeau J, Krampera M, Le Blanc K, Martin I, Moniz K, Nolta I, Phinney DG, Shi Y, Szczepiorkowski ZM, Tarte K, Weiss DJ, Ashford P. Consensus ICCBBA-ISCT statement on standard nomenclature abbreviations for the tissue of origin of Mesenchymal Stromal Cells. Cytotherapy. JIF: 4.15

  • Mathews S, Rabani R, Rasti M, Viswanathan S. In-house abbreviated qualification of a real time PCR method and strategies to amplify mycoplasma detection in human mesenchymal stromal cells. Cytotherapy. JIF: 4.15

  • Lin-Gibson S, Lin NJ, Jackson S, Viswanathan S, Zylberberg C, Wolfrum J, Basu S, Roy K, Marshall D, McFarland R, Hoover S, Rietze R, Getz A, Henke D. Standards efforts and landscape for rapid microbial testing methodologies in regenerative medicine. Cytotherapy. JIF: 4.15

  • Galipeau J, Krampera M, Leblanc K, Nolta JA, Phinney DG, Shi Y, Tarte K, Viswanathan S, Martin I. Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy. JIF: 4.15

  • Abji F, Rasti M, Gómez-Aristizábal A, Muytjens C, Saifeddine M, Mihara K, Motahhari M, Gandhi R, Viswanathan S, Hollenberg MD, Oikonomopoulou K, Chandran V. Proteinase-mediated macrophage signalling in psoriatic arthritis. Frontiers in Immunology. JIF: 7.0

2020

  • Khoury M, Rocco PRM, Phinney DG, Krampera M, Martin I, Viswanathan S, Nolta JA, LeBlanc K, Galipeau J, Weiss DJ. Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. Cytotherapy. 2020 JIF: 4.15
  • Rockel JS, Rabani R, Viswanathan S. Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases. Seminars in Cell and Developmental Biology. JIF: 6.14

2019

  • Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, Nolta J, Phinney DG, Sensebe L. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. JIF: 4.15

  • Chisholm J, Ruff C, Viswanathan S. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy. JIF: 4.15

  • Chahal J, Gómez-Aristizábal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, Chisholm J, Weston A, Chiovitti J, Keating A, Kapoor M, Ogilvie-Harris DJ, Syed KA, Gandhi R, Mahomed NN, Marshall KW, Sussman MS, Naraghi AM, Viswanathan S. Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation. Stem Cells Translational Medicine.   JIF:6.0

  • Bubela T, Boch R, Viswanathan S. Recommendations for regulating the environmental risk of shedding for gene therapy and oncolytic viruses in Canada. Frontiers in Medicine IF: 3.6

  • Hamilton AM, Cheung WY, Gómez-Aristizábal A, Sharma A, Nakamura S, Chaboureau A, Bhatt S, Rabani R, Kapoor M, Foster PJ, Viswanathan S. Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of action. PLoS One. JIF: 2.8

  • Robb KP, Fitzgerald JC, Barry F, Viswanathan S. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy. JIF: 4.15

  • Chan MWY, Viswanathan S. Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases. Cytotherapy. (2019) JIF: 4.15

  • Gómez-Aristizábal A, Gandhi R, Mahomed NN, Marshall KW, Viswanathan S. Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort study. Arthritis Research Therapy. JIF: 5.13

© 2026 by Sowmya Viswanathan, PhD. Powered and secured by Wix

bottom of page